Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848572 | 1.00 | LMNA (0.33) | LMNACYP2C9OPRM1HSD11B1 | |
| SCHEMBL13791826 | 0.90 | MAPK1 (0.37) | — | |
| SCHEMBL19763596 | 0.86 | NCF1 (0.32) | — | |
| SCHEMBL20071156 | 0.84 | — | — | |
| SCHEMBL27280941 | 0.80 | LMNA (0.31) | LMNACYP2C9OPRM1 | |
| SCHEMBL761435 | 0.80 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL9963382 | 0.80 | LMNA (0.35) | LMNACYP2C9 | |
| SCHEMBL24816724 | 0.79 | HRH3 (0.30) | — | |
| SCHEMBL9884491 | 0.79 | HRH3 (0.30) | — | |
| SCHEMBL12267691 | 0.79 | HRH3 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| WO-2023192586-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
| WO-2023098656-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE, LTD. (GB) | 2023-06-08 | — | — | WO | disclosed |
| WO-2022189810-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2022-09-15 | — | — | WO | disclosed |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | ANGEX PHARMACEUTICAL, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | ANGEX PHARMACEUTICAL, INC. | 2021-06-03 | — | — | US | disclosed |
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | CORVUS PHARMACEUTICALS, INC. (US) | 2021-05-18 | — | — | US | disclosed |
| WO-2020108613-A1 | HETEROAROMATIC DERIVATIVES FOR USE AS REGULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏豪森药业集团有限公司 | 2020-06-04 | — | — | WO | disclosed |
| WO-2018089261-A2 | COMPOUNDS AND METHODS FOR MODULATING INTERLEUKIN-2-INDUCIBLE T-CELL KINASE | CORVUS PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008314-B2 | Compounds and methods for modulating interleukin-2-inducible t-cell kinase | IL2, NFATC1, IL2RA | LMNA 4243/4885CYP2C9 4795/4885OPRM1 4350/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | LMNA 1656/4885CYP2C9 3608/4885OPRM1 4472/4885 |
| US-20230183216-A1 | PYRIDIZIN-3(2H)-ONE DERIVATIVES | PIR, CYP3A43, CYP1A2 | LMNA 678/4885CYP2C9 168/4885OPRM1 549/4885 |
| US-11358949-B2 | Carbamate and urea compounds as multikinase inhibitors | UCK2, ULK2, CDK9 | LMNA 3217/4885CYP2C9 1950/4885OPRM1 4192/4885 |
| US-20210163445-A1 | CARBAMATE AND UREA COMPOUNDS AS MULTIKINASE INHIBITORS | UCK2, ULK2, CDK9 | LMNA 3217/4885CYP2C9 1950/4885OPRM1 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.